Anticoagulants Medicine Enoxaparin Sodium Injection 40mg/0.4ml Shinepharm

• Application: Internal Medicine
• Usage Mode: Injection
• Suitable for: Elderly, Children, Adult
• State: Liquid
• Shape: Powder
• Type: Western Medicines
• Model NO.: AMC14084-01
• Pharmaceutical Technology: Chemical Synthesis
• Function: Anticoagulants
• Standard Available: Bp, Cp
• Delivery Time: 30~60 Days
• OEM/ODM: Support
• Transport Package: 2′s/Box
• Specification: 40MG/0.4ML
• Trademark: Shinepharm
• Origin: China
• HS Code: 300490909
• Production Capacity: 1000000 Boxes/Month

Product Description

Indications:
Enoxaparin sodium injection is a low molecular weight heparin indicated for:
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness
Inpatient treatment of acute DVT with or without pulmonary embolism
Outpatient treatment of acute DVT without pulmonary embolism
Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction.
Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI]
Dosage and Administration:
Evaluate all patients for a bleeding disorder before starting enoxaparin sodium injection treatment, unless treatment is urgently needed.
Do not administer enoxaparin sodium injection by intramuscular injection.
Administer enoxaparin sodium injection by intravenous or subcutaneous injection only.
Storage instructions:
Store in a cool and dry place,below 25°C.

Testing terms	Standards	Results
Character	A clear, colorless to pale yellow liquid.	A clear, faint yellow liquid.
pH	5.5-7.5	6.7
Clarity and color	Clear Colour: BY5 or better	Clear <Y5
Bacterial endotoxin	<0.01EU/AXaUSPU	<0.01EU/AXaUSPU
Filling volume	Should meet the requirement.	Complies
Free sulfate content	≤0.12%	0.02%
Sterlity	Should meet the requirement.	Complies
Particulate matter	≥10um:not exceeding 6000 225μm:not exceeding 600	8vial 0/vial
Anti-factor Xa potency	90.0%-110.0% of stated potency	100.8%
Anti-factor lla potency	20.0%~35.0% of Anti-factor Xa potency	23.4%